Drug intelligence / Profile preview

Monoacylglycerol oil

Development stage: Unknown
Lead developer: Nestlé
Administration: Oral

Overview

Monoacylglycerol oil (MAG oil) is an oral nutritional supplement, specifically an enriched sn-1(3)-MAG oil, developed by Nestlé. It is designed to enhance the absorption and delivery of long-chain polyunsaturated fatty acids (LC-PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), to the circulatory system. This is particularly beneficial in individuals experiencing lipid malabsorption conditions, as the sn-1(3)-MAG structure is thought to require minimal digestion before crossing the gut barrier, thereby improving the bioavailability of these essential fatty acids. Clinical studies have investigated its tolerance and safety in healthy adolescents and its efficacy in humans with induced lipid malabsorption.

Other names: MAG oil oral nutritional supplement (ONS)enriched sn-1(3)-MAG oil

Beyond the preview

Go deeper on Monoacylglycerol oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monoacylglycerol oil.

Explore the full profile